title: A comparative study on effects of doxorubicin alone or mixed with lipiodol given through the hepatic artery or portal vein for liver tumors in rats.
abstract: Vascular feeding of metastatic liver tumors at early stage is uncertain. It is controversial whether anticancer agents should be given through the hepatic artery or portal vein. In order to clarify this point, a rat model of liver metastases generated by an intraportal injection of syngeneic tumor cells was used to determine the optimal regional chemotherapeutic modality for early hepatic metastases. The rats given the tumor cells through the portal vein were placed into 5 groups: In groups I and II, Adriamycin (ADR) 4 mg/kg alone was given either into the hepatic artery or into the portal vein, respectively, 24 h after the inoculation of tumor cells. In groups III and IV, ADR mixed with lipiodol (lipiodolized ADR) 4 mg/kg was given into the hepatic artery or into the portal vein, respectively, 24 h after inoculation. For the group V rats, no treatment was given after inoculation of the tumor. When a comparison was made with regard to the forms of anticancer drug administered, statistically significant differences in survival rates were recognized between groups I and III (p < 0.001), and groups II and IV (p < 0.05). The anticancer agent not mixed with lipiodol and given through the hepatic artery had a more preventive effect than that given through the portal vein. Thus, we conclude that administration of ADR not mixed with lipiodol and given through the hepatic artery is the preferred modality for treating early metastatic liver tumors.
authors.affiliation: Department of Surgery II, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Utsunomiya
authors.forename: T
authors.initials: T
authors.lastname: Kanematsu
authors.forename: T
authors.initials: T
authors.lastname: Matsumata
authors.forename: K
authors.initials: K
authors.lastname: Shirabe
authors.forename: M
authors.initials: M
authors.lastname: Yamagata
authors.forename: K
authors.initials: K
authors.lastname: Sugimachi
mesh_terms: D000818:Animals; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000517:prevention & control / Q000556:secondary; D004317:Doxorubicin / Q000008:administration & dosage* / Q000378:metabolism / Q000494:pharmacology; D007261:Infusions, Intra-Arterial; D007262:Infusions, Intravenous; D007459:Iodized Oil / Q000008:administration & dosage*; D008114:Liver Neoplasms, Experimental / Q000098:blood supply / Q000517:prevention & control* / Q000556:secondary*; D009368:Neoplasm Transplantation; D011168:Portal System; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D007459:Iodized Oil; D004317:Doxorubicin